Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
2
33%
Ph phase_1
1
17%
Ph not_applicable
2
33%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 32 (33.3%)
N/A2 (33.3%)

Trials by Status

completed467%
recruiting117%
withdrawn117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744
completedphase_3

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT03287232
withdrawnphase_3

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
completednot_applicable

The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy

NCT02602366
completedphase_1

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04098744Phase 2

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Recruiting
NCT03287232Phase 3

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Completed
NCT03619005Phase 3

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Withdrawn
NCT02602366Not Applicable

The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy

Completed
NCT02569697Phase 1

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

Completed
NCT02534779Not Applicable

Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products

Completed

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6